Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach to China

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Andrew von Eschenbach and Deputy Commissioner for International and Special Programs Murray Lumpkin met with China's minister of health and commissioner of China's food and drug agency as the two countries try to finalize a memorandum of agreement on the import safety of food, drugs and medical devices (1"The Tan Sheet" Aug. 20, 2007, p. 14). While withholding details of the MOA, Lumpkin noted that FDA's "preference is obviously not to have to catch problems in the products at our borders ... but prevent them at the source of their manufacturer." Von Eschenbach suggested the MOA will be finalized in early December, in time for HHS Secretary Mike Leavitt's visit to China. The meeting in Shanghai is the latest effort from the Bush administration's Interagency Working Group on Import Safety established in July...

You may also be interested in...



China Commits To Tightening Food Safety Supervision As MOA Talks Begin

A spokesman at the Chinese embassy in Washington says China will intensify its food safety supervision as U.S. and Chinese officials in Beijing begin work on a memorandum of agreement on food and feed safety

Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'

Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative.” The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.

First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market

A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel